{'fraction_non_alphanumeric': 0.02460456942003515, 'fraction_numerical': 0.0, 'mean_word_length': 6.5, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Evaluation of aprepitant for acute chemotherapy‐induced nausea and vomiting in children and adolescents with acute lymphoblastic leukemia receiving high‐dose methotrexate

Chemotherapy‐induced nausea and vomiting (CINV) negatively impacts patients’ quality of life. The emetogenicity of high‐dose methotrexate in children and adolescents with cancer is incompletely characterized. At our institution, a number of patients with acute lymphoblastic leukemia (ALL) have received aprepitant with courses of high‐dose methotrexate after poor CINV control with prior courses.